Cognistat

Cognistat Cognistat is a rapid cognitive-assessment tool used to screen and quantify neuropsychological problems across a broad spectrum of patients.

It is one of the most widely used cognitive screening tools in the world, with over 300 independent scientific articles (www.cognistat.com) describing its use in patients with dementia, MCI, stroke, traumatic brain injury, major psychiatric disorders and substance abuse. Cognistat quickly assesses five major domains of cognitive functioning: orientation, attention, language, spatial skills (ie: co

nstruction), memory, calculation and reasoning. Additionally, the level of consciousness, orientation and attention are assessed independently. A profile of the patient’s cognitive strengths and weaknesses with respect to the key cognitive domains is generated; and in particular, memory and spatial skills, which are sensitive indicators of MCI.

07/02/2025

🧠 Brain Plasticity in Action – Catch It Early
New insights show that the brain’s ability to reorganize and recover—neuroplasticity—is most dynamic during the early stages of cognitive decline. Timing matters more than ever.
At Cognistat, our rapid (20‑minutes) web-based cognitive screening - language, memory, reasoning, calculation, and construction empowers clinicians to detect subtle cognitive shifts long before they escalate.

Implement Cognistat in your care workflows to:
🎯 Identify early-stage neurocognitive changes
💡 Intervene when the brain is still highly adaptable
📊 Track patient progress over time with repeatable, validated assessments
Join the conversation—how is your team leveraging early screening to support brain health?

06/20/2025

📈 What Gets Measured, Gets Managed
Cognitive health is measurable, and tracking it leads to better care.
With Cognistat’s repeatable testing, you can:
• Monitor change over time
• Measure response to treatment
• Guide care planning with confidence
One tool. Multiple insights.

06/17/2025

🧠 Brain Plasticity in Action – Catch It Early
New research underscores a powerful truth: the brain’s ability to reorganize and recover—neuroplasticity—is greatest in early stages of decline. That’s why the timing of assessment is everything.
At Cognistat, we empower clinicians to detect subtle cognitive changes before they escalate. Our rapid, web‑based screening—language, memory, reasoning, calculation, and construction—enables early insight and intervention in just ~20 minutes.
🔎 When you integrate Cognistat into your workflow, you're not just screening—you’re catching the brain in its most adaptable state.
How are you working with your team to identify cognitive shifts early?

06/12/2025

🧠 Building on 400+ Publications: Cognistat’s Legacy of Evidence-Based Screening.
For over four decades, Cognistat has been validated by 400+ peer-reviewed studies across dementia, stroke, brain injury, delirium, and more.
📌 Our tool is more than quick – it's proven:
Multi-domain cognitive assessment (language, memory, reasoning, calculation, construction)
Applicable from adolescents to seniors.
Backed by decades of academic and clinical research.
At Cognistat, scientific rigor meets clinical efficiency.
Let's talk if you’re looking for a validated, trustworthy cognitive screening solution.
What evidence matters most to your clinical team? 💬👇

06/11/2025

🧠 Blood Biomarkers: A Game-Changer in Early Alzheimer’s Detection
Exciting news: the FDA recently approved Lumipulse, a blood test that screens for Alzheimer’s with up to 97% accuracy—no needles, no brain scans. Meanwhile, a study from UCSF indicates that even “normal” B12 levels may not be optimal for brain health, suggesting cognitive decline risks go undetected without better biomarkers.
These breakthroughs spotlight a powerful truth: brain health can now be screened through a simple blood draw, increasing access and initiating earlier interventions.
At Cognistat, we already support early, proactive cognitive screening. As blood tests grow more reliable and accessible, combining them with tools like ours can maximize early detection and patient care.
🔍 How do you view the integration of blood biomarkers with cognitive tools in your practice?

06/10/2025

🖥️ Clinician‑supervised tests via video call show strong validity compared to in-person evaluations.
⏱️ With versions like a 20‑minute full Cognistat online, professionals can swiftly adapt to any care setting—even via phone or video.
Ready to bring cognitive care beyond the clinic—even into living rooms and care facilities. Early detection starts with accessibility.

06/09/2025

🌐 Telehealth Meets Cognitive Screening
With the rise of telehealth, accessible and reliable remote cognitive assessments have never been more essential. Cognistat’s secure online platform makes it possible to screen for Dementia, MCI, or delirium—whether in-clinic or on the go—without compromising clinical rigor. Studies show virtual tools can support earlier diagnosis and simplify follow-up monitoring, particularly for patients in remote or underserved regions.

06/03/2025

📊 Mild Cognitive Impairment: Often Missed, Rarely Talked About
Mild Cognitive Impairment (MCI) affects up to 20% of adults over 65, but many go undiagnosed.
Why? Because signs are subtle, and standard checkups don’t include cognitive screening.
🧠 At Cognistat, MCI detection has always been built in.
Let’s bridge the gap between what we observe and act on.

05/29/2025

🔍 We Want to Hear from You: What Are Your Biggest Challenges in Brain Health Care?
At Cognistat, we’re committed to advancing the conversation around brain health. We know the best insights often come from those on the front lines: YOU 🫵.
Whether you're a clinician, researcher, caregiver, or policymaker, we’d love to hear from you:
💬 What challenges are you facing in brain health care today?
🧩 Are there gaps in assessment tools, data integration, or patient engagement?
🛠️ What innovations do you wish existed?
Your experiences and perspectives help shape the future of cognitive care. Drop a comment below or send us a message—we're listening.

05/27/2025

🔍Cognitive decline doesn’t always walk in the door with a label.
Here are 3 early signs that might go unnoticed:
🔹 A patient hesitates on details they once remembered easily.
🔹 They struggle to adapt to new routines or settings.
🔹 Caregivers express quiet concerns, but no one has screened them.
These are the moments where proactive cognitive screening matters the most.
🧠 Cognistat makes it possible—in just 15 minutes.

05/26/2025

💡Did You Know?
🧠 Cognitive decline can begin 10+ years before dementia symptoms appear.
🩺 Yet cognitive screening is still not part of routine care.
We can change that.
Cognistat supports clinicians with fast, accurate tools to catch what might be missed.
Because by the time symptoms are “clear,” much of the damage has already happened.

05/15/2025

🩺 “They seem fine.”

That’s what many clinicians hear before subtle signs of Mild Cognitive Impairment (MCI) become clear.

Here are 3 quiet cues you might notice:

✔️ A well-functioning patient asking for help with simple tasks.

✔️ Difficulty keeping track of appointments.

✔️ A partner saying, “They’re just not quite themselves lately.”

Cognistat was designed to catch these early shifts—before they escalate.

Because brain health deserves the same priority as physical health.

Address

Montreal, QC

Alerts

Be the first to know and let us send you an email when Cognistat posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Our Story

Cognistat is a rapid cognitive-assessment tool used to screen and quantify neuropsychological problems across a broad spectrum of patients. It is one of the most widely used cognitive screening tools in the world, with over 300 independent scientific articles (www.cognistat.com) describing its use in patients with dementia, MCI, stroke, traumatic brain injury, major psychiatric disorders and substance abuse. Cognistat quickly assesses five major domains of cognitive functioning: orientation, attention, language, spatial skills (ie: construction), memory, calculation and reasoning. Additionally, the level of consciousness, orientation and attention are assessed independently. A profile of the patient’s cognitive strengths and weaknesses with respect to the key cognitive domains is generated; and in particular, memory and spatial skills, which are sensitive indicators of MCI.